Dabur India
- Market Cap
- ₹69,734 Cr
- P/E
- 34.42
Key Fundamentals
MidcapPersonal ProductsFMCGPrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 20.30%
- Debt to Equity
- 0.13
- EPS (TTM)
- ₹11.42
- Book Value
- ₹64.78
- Market Cap
- ₹69,734 Cr
- P/E (TTM)
- 34.42
- P/B
- 6.07
- ROE
- 17.00%
- Dividend Yield
- 0.90%
- EBITDA
- ₹3,052 Cr
- 52W High
- ₹534.00
- 52W Low
- ₹354.30
- Day Range
- ₹390.35 – ₹396.40
- Volume
- 29,38,384
Peer Comparison
Fast Moving Consumer Goods › Personal Products › Personal Care
| 919.50 | 47.57 | 94,093 | 7.46 | 1.67% | 16.10% | 18.80% | 16,537 | 1,978 | |
| 393.10 | 34.42 | 69,734 | 6.07 | 0.92% | 17.00% | 20.30% | 13,924 | 2,001 | |
| 365.65 | 290.20 | 49,168 | 87.48 | 1.38% | 27.60% | 33.90% | 602 | 169 | |
| 1,760.00 | 35.15 | 47,869 | 29.60 | 1.42% | 82.70% | 108.00% | 6,391 | 1,362 | |
| 7,090.50 | 33.80 | 23,105 | 21.51 | 3.31% | 66.50% | 90.70% | 3,211 | 683 | |
| 7,020.00 | 29.34 | 22,787 | 25.78 | 3.73% | 115.00% | 157.00% | 4,240 | 776 | |
| 422.20 | 24.76 | 18,429 | 6.30 | 1.21% | 26.20% | 28.10% | 4,204 | 747 | |
| Median 7 companies | 919.50 | 34.42 | 47,869 | 21.51 | 1.42% | 27.60% | 33.90% | 4,240 | 776 |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 78
- Strong
- Returns, margins, earnings quality 22% weight
- Valuation
- 36
- Poor
- Cheap vs sector & own history 24% weight
- Growth
- 50
- Average
- Sales & profit trajectory 9% weight
- Financial Health
- 85
- Strong
- Solvency, leverage, coverage 9% weight
- Momentum
- 38
- Weak
- Trend strength, vol-adjusted 12% weight
- Ownership
- 44
- Weak
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
1- Company has been maintaining a healthy dividend payout of 70.1%
Weaknesses
1- The company has delivered a poor sales growth of 6.65% over past five years.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bullish | 5 | 7 | 7 |
| Oscillators | Neutral | 1 | 7 | 1 |
| Moving Averages | Strong Bullish | 4 | 0 | 6 |
Oscillators
Neutral
Overall
Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 58.68
- Neutral
- MACD (12,26,9)
- 2.41
- Bullish
- SMA (50)
- 380.00
- Bullish
- SMA (200)
- 427.41
- Bearish
As of
Analyst Rating
22 of 37 analysts rate Buy, 12 Hold, 3 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 10Y | +5.42% |
|---|---|
| 5Y | +6.65% |
| 3Y | +4.59% |
| 1Y | +5.01% |
| TTM | +8.94% |
Net profit
| 10Y | +4.07% |
|---|---|
| 5Y | +1.97% |
| 3Y | +3.19% |
| 1Y | +7.41% |
| TTM | +12.29% |
Operating cash flow
| 10Y | +8.07% |
|---|---|
| 5Y | +4.05% |
| 3Y | +20.12% |
| 1Y | +29.79% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | −0.94 pp |
|---|---|
| 5Y | −2.37 pp |
| 3Y | −0.18 pp |
| 1Y | +0.13 pp |
| TTM | −0.06 pp |
Revenue by year
| Mar 2017 | ₹7,614 Cr |
|---|---|
| Mar 2018 | ₹7,722 Cr |
| Mar 2019 | ₹8,515 Cr |
| Mar 2020 | ₹8,685 Cr |
| Mar 2021 | ₹9,562 Cr |
| Mar 2022 | ₹10,889 Cr |
| Mar 2023 | ₹11,530 Cr |
| Mar 2024 | ₹12,404 Cr |
| Mar 2025 | ₹12,563 Cr |
| Mar 2026 | ₹13,193 Cr |
Net profit by year
| Mar 2017 | ₹1,280 Cr |
|---|---|
| Mar 2018 | ₹1,358 Cr |
| Mar 2019 | ₹1,446 Cr |
| Mar 2020 | ₹1,448 Cr |
| Mar 2021 | ₹1,695 Cr |
| Mar 2022 | ₹1,742 Cr |
| Mar 2023 | ₹1,701 Cr |
| Mar 2024 | ₹1,811 Cr |
| Mar 2025 | ₹1,740 Cr |
| Mar 2026 | ₹1,869 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Dabur India Ltd trades at ₹384.3 as of 2026-11-17 with a market cap of ₹68,173 crore, sitting 28% below its 52-week high of ₹534. The company shows improving recent momentum with TTM sales growth of 9% and TTM profit growth of 13%, though longer-term compounded profit growth has been subdued at 2-4% over 3-5 year periods. The balance sheet remains conservatively managed with a debt-to-equity ratio of 0.11.
- Near-zero leverage with a debt-to-equity ratio of just 0.11, providing significant financial flexibility and resilience against interest rate cycles
- TTM profit growth has accelerated to 13%, a meaningful improvement over the 3-year compounded profit growth of 4% and 5-year compounded profit growth of 2%
- Healthy dividend payout ratio of 70.1%, reflecting shareholder-friendly capital allocation with a current dividend yield of 0.92%
- ROCE of 20.96% indicates efficient capital deployment and strong underlying business economics
- TTM sales growth of 9% represents a clear acceleration compared to the 5-year compounded sales growth of 7% and 3-year compounded sales growth of 5%
- Stock is trading at ₹384.3, only about 8% above its 52-week low of ₹354.3, which may reflect a degree of pessimism already priced in
- 10-year ROE average of 21% demonstrates the company's ability to generate consistent returns on shareholder equity over long periods
- Stock has delivered a 1-year return of -26% and a 5-year CAGR of -9%, indicating sustained value destruction for shareholders over multiple time horizons
- PE ratio of 33.65 is elevated relative to the 5-year compounded profit growth of just 2%, implying the stock is priced for significantly higher growth than it has historically delivered
- Poor sales growth of 6.65% over the past five years for an FMCG company suggests limited ability to drive volume or pricing gains
- ROE has trended downward from a 10-year average of 21% to 17% in the last year, signalling deteriorating return efficiency
- Price-to-book ratio of 5.93 is demanding given that the 3-year stock CAGR stands at -11%, meaning investors have paid a premium while returns have eroded
- 10-year stock CAGR of just 3% has significantly underperformed broader market indices over the same period
- 3-year compounded profit growth of 4% and 5-year compounded profit growth of 2% reflect structural earnings stagnation over medium-term horizons
- The stock sits 28% below its 52-week high of ₹534, and the persistent downtrend from that level suggests the market has been re-rating the company lower
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Dabur delivered solid Q2FY27 growth with revenue up 11.6% and PAT up 11.7%, supported by premiumisation and distribution efficiency gains under Project Saksham. The SEBI administrative warning for delayed FDA disclosure is a governance blemish but the company says it had no financial impact. Leadership transition to a new CEO and strengthened audit oversight signal organisational reset. Near-term trajectory looks constructive if the Ignite strategy translates elevated A&P spending into sustained volume growth.
- SEBI warning on delayed disclosure Nov 06
SEBI issued an administrative warning to Dabur India for delaying disclosure of a US FDA warning letter received on July 24, 2026, citing violation of Regulation 30(6)(iii) of LODR Regulations. Repeated lapses could trigger enforcement action under the SEBI Act, 1992.
- Subsidiary shut via liquidation Nov 11
Dabur India closed its subsidiary Atlanta Body and Health Products through a voluntary liquidation process, indicating an orderly wind-down of that business line.
- Strong Q2FY27 revenue and PAT Nov 10
Q2FY27 consolidated revenue rose 11.6% YoY to ₹3,563 crore with PAT up 11.7%. Premium portfolio now contributes 20% of domestic business, targeting 23% by FY28.
- Ignite strategy boosts A&P spend Nov 10
New 'Ignite' strategy plans a 150-200 bps increase in advertising and promotion spend for core brands. Project Saksham reduced distributor count by 43% while doubling throughput.
- EY appointed as joint auditor Nov 04
Dabur's board appointed Ernst & Young LLP as Joint Internal Auditor alongside PwC Services LLP for the period ending March 31, 2028, strengthening internal audit oversight.
- New CEO and director appointments Nov 04
Herjit Singh Bhalla appointed Whole-time Director and CEO-India effective Nov 14, 2026, replacing Mohit Malhotra. Postal ballot for his formal appointment and that of independent director Gopal Krishna Jain runs Nov 21 to Dec 20, 2026.
- Interim dividend record date set Nov 03
Dabur fixed November 10, 2026, as the record date for its FY27 interim dividend, subject to board approval on November 4.
- KMP contact details updated Nov 13
Dabur updated Key Managerial Personnel contact details effective Nov 14, 2026. Compliance Officer Ashok Kumar Jain serves until his superannuation on November 30, 2026.
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,204 | 3,255 | 2,815 | 3,349 | 3,029 | 3,355 | 2,830 | 3,405 | 3,191 | 3,559 | 3,038 | 3,764 | 3,563 |
| Expenses | 2,543 | 2,588 | 2,348 | 2,694 | 2,476 | 2,673 | 2,403 | 2,737 | 2,603 | 2,825 | 2,577 | 3,024 | 2,931 |
| Operating Profit | 661 | 667 | 466 | 655 | 553 | 682 | 427 | 667 | 588 | 734 | 461 | 741 | 632 |
| OPM % | 21% | 20% | 17% | 20% | 18% | 20% | 15% | 20% | 18% | 21% | 15% | 20% | 18% |
| Other Income | 116 | 127 | 129 | 129 | 152 | 128 | 141 | 144 | 140 | 141 | 175 | 173 | 172 |
| Interest | 28 | 36 | 35 | 33 | 47 | 44 | 39 | 35 | 40 | 31 | 40 | 37 | 39.59 |
| Depreciation | 98 | 97 | 107 | 109 | 111 | 109 | 117 | 114 | 115 | 117 | 122 | 121 | 119 |
| Exceptional Items | — | — | — | — | — | — | — | — | — | −15.05 | — | — | — |
| PBT | 651 | 662 | 453 | 643 | 546 | 657 | 412 | 663 | 573 | 711 | 475 | 756 | 646 |
| Tax % | 22% | 23% | 25% | 23% | 24% | 22% | 24% | 23% | 22% | 22% | 24% | 22% | 23% |
| Net Profit | 507 | 506 | 341 | 494 | 418 | 516 | 313 | 508 | 445 | 554 | 362 | 586 | 499 |
| EPS (₹) | 2.91 | 2.90 | 1.97 | 2.82 | 2.40 | 2.95 | 1.81 | 2.90 | 2.55 | 3.16 | 2.08 | 3.33 | 2.85 |
| YoY Sales growth | 7 | 7 | 5 | 7 | −5 | 3 | 1 | 2 | 5 | 6 | 7 | 11 | 12 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 7,795 | 7,780 | 7,614 | 7,722 | 8,515 | 8,685 | 9,562 | 10,889 | 11,530 | 12,404 | 12,563 | 13,193 | 13,924 |
| Expenses | 6,475 | 6,261 | 6,102 | 6,104 | 6,775 | 6,892 | 7,560 | 8,637 | 9,367 | 10,004 | 10,247 | 10,743 | 11,356 |
| Operating Profit | 1,320 | 1,518 | 1,512 | 1,617 | 1,740 | 1,792 | 2,002 | 2,252 | 2,162 | 2,400 | 2,316 | 2,450 | 2,568 |
| OPM % | 17% | 20% | 20% | 21% | 20% | 21% | 21% | 21% | 19% | 19% | 18% | 19% | 18% |
| Other Income | 154 | 217 | 296 | 305 | 222 | 305 | 325 | 393 | 445 | 482 | 550 | 600 | 645 |
| Interest | 40 | 48 | 54 | 53 | 60 | 50 | 31 | 39 | 78 | 124 | 164 | 145 | 147 |
| Depreciation | 115 | 133 | 143 | 162 | 177 | 220 | 240 | 253 | 311 | 399 | 446 | 469 | 479 |
| Exceptional Items | — | — | — | −14.54 | — | −100 | — | −85 | — | — | — | −15.05 | — |
| PBT | 1,319 | 1,554 | 1,611 | 1,693 | 1,725 | 1,728 | 2,057 | 2,269 | 2,219 | 2,359 | 2,257 | 2,422 | 2,586 |
| Tax % | 19% | 19% | 21% | 20% | 16% | 16% | 18% | 23% | 23% | 23% | 23% | 23% | — |
| Net Profit | 1,068 | 1,254 | 1,280 | 1,358 | 1,446 | 1,448 | 1,695 | 1,742 | 1,701 | 1,811 | 1,740 | 1,869 | 2,000 |
| EPS (₹) | 6.07 | 7.11 | 7.25 | 7.69 | 8.17 | 8.18 | 9.58 | 9.84 | 9.64 | 10.40 | 9.97 | 10.68 | 11.42 |
| Div. Payout % | 33% | 32% | 31% | 81% | 34% | 37% | 50% | 53% | 54% | 53% | 80% | 77% | — |
| Sales growth | 10 | 0 | −2 | 1 | 10 | 2 | 10 | 14 | 6 | 8 | 1 | 5 | 9 |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 176 | 176 | 176 | 176 | 177 | 177 | 177 | 177 | 177 | 177 | 177 | 177 | 177 |
| Reserves | 3,178 | 3,995 | 4,671 | 5,530 | 5,455 | 6,429 | 7,487 | 8,205 | 8,796 | 9,689 | 10,623 | 11,242 | 11,315 |
| Borrowings | 734 | 805 | 975 | 938 | 699 | 522 | 509 | 1,030 | 1,174 | 1,365 | 950 | 1,287 | 1,445 |
| Other Liabilities | 2,019 | 1,956 | 1,910 | 2,058 | 2,106 | 2,209 | 2,661 | 2,872 | 3,505 | 3,885 | 4,479 | 4,773 | 4,932 |
| Total Liabilities | 6,106 | 6,932 | 7,732 | 8,702 | 8,437 | 9,337 | 10,833 | 12,284 | 13,652 | 15,116 | 16,230 | 17,480 | 17,869 |
| Fixed Assets | 1,877 | 1,667 | 1,958 | 2,028 | 1,969 | 2,253 | 2,243 | 2,308 | 3,579 | 3,815 | 3,990 | 3,938 | 3,797 |
| CWIP | 50 | 45 | 42 | 42 | 64 | 147 | 147 | 168 | 175 | 232 | 169 | 139 | 163 |
| Investments | 1,813 | 2,691 | 3,240 | 3,805 | 3,359 | 2,800 | 4,160 | 6,220 | 6,265 | 6,933 | 7,468 | 8,947 | 8,898 |
| Other Assets | 2,365 | 2,529 | 2,492 | 2,827 | 3,045 | 4,137 | 4,283 | 3,589 | 3,633 | 4,136 | 4,603 | 4,456 | 5,011 |
| Total Assets | 6,106 | 6,932 | 7,732 | 8,702 | 8,437 | 9,337 | 10,833 | 12,284 | 13,652 | 15,116 | 16,230 | 17,480 | 17,869 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 1,047 | 1,187 | 1,227 | 1,092 | 1,499 | 1,614 | 2,115 | 1,802 | 1,488 | 2,013 | 1,987 | 2,579 |
| Investing | −876 | −730 | −807 | −541 | 338 | −517 | −1,404 | −1,273 | −583 | −971 | −448 | −1,279 |
| Financing | −417 | −374 | −339 | −577 | −1,888 | −1,043 | −613 | −490 | −1,035 | −1,161 | −1,405 | −1,236 |
| Net Cash Flow | −245 | 82 | 81 | −27 | −51 | 54 | 97 | 38 | −130 | −119 | 133 | 64 |
| Free Cash Flow | 796 | 998 | 741 | 891 | 1,274 | 1,213 | 1,808 | 1,433 | 1,003 | 1,453 | 1,448 | 2,180 |
| CFO/EBITDA | 97 | 97 | 102 | 88 | 106 | 107 | 122 | 97 | 92 | 104 | 103 | 122 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 33 | 38 | 31 | 33 | 36 | 34 | 21 | 22 | 27 | 26 | 26 | 20 |
| Inventory Days | 136 | 150 | 153 | 169 | 154 | 164 | 178 | 169 | 158 | 149 | 175 | 166 |
| Days Payable | 153 | 182 | 181 | 190 | 172 | 176 | 197 | 178 | 171 | 186 | 215 | 212 |
| Cash Conversion Cycle | 16 | 6 | 3 | 13 | 17 | 22 | 3 | 12 | 14 | −10 | −14 | −26 |
| Working Capital Days | −17 | 0 | −7 | −1 | −5 | 9 | −9 | −14 | −13 | −17 | −13 | −42 |
| ROCE % | 36% | 35% | 31% | 28% | 28% | 28% | 27% | 27% | 23% | 22% | 20% | 20% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Dabur India insights
74 extracted metrics across FY07–FY27.
Documents
- Q2 FY27 concall · Nov 2026PPT
- Q2 FY27 concall · Nov 2026Transcript PPT Recording
- Q1 FY27 concall · Aug 2026Transcript PPT
- Q4 FY26 concall · May 2026Transcript PPT
- 17 Nov 2026
- 12 Mar 2026
- 20 Nov 2025
- 20 Mar 2025
- 21 Nov 2024
- General announcements 13 Nov 2026
Frequently Asked Questions about Dabur India
What does Dabur India Ltd do?
Where is Dabur India Ltd (DABUR) listed?
Which sector does Dabur India Ltd belong to?
What is the market capitalisation of Dabur India Ltd?
What is the PE ratio of Dabur India Ltd?
What is the 52-week high and low of Dabur India Ltd?
Does Dabur India Ltd pay dividends?
What is the Return on Equity (ROE) of Dabur India Ltd?
Company Information
Dabur is India’s leading FMCG, Ayurvedic and natural health care company with wide network distribution across world.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/DABUR.md for Dabur India Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.